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IFNAR /Bluetongue is a severe, economically important disease of ruminants that is widely distributed in tropical
and temperate regions around the world. It is associated with major production losses, restrictions of ani-
mal movements and trade, as well as costs associated with developing and implementing effective
surveillance and control measures. Mammalian hosts infected with bluetongue virus (BTV) generate a
protective neutralising antibody response targeting the major BTV outer-capsid protein and serotype-
specific antigen, VP2. BTV VP2 proteins that have been expressed in plants are soluble, with a native con-
formation displaying neutralising epitopes and can assemble with other BTV structural proteins to form
virus-like particles (VLPs).
His-tagged VP2 proteins of BTV serotypes 4 and 8 were transiently expressed in Nicotiana benthamiana
then purified by immobilised metal affinity chromatography (IMAC). Antisera from IFNAR / mice
prime/boost vaccinated with the purified proteins, were shown to contain VP2-specific antibodies by
Indirect ELISA (I-ELISA), western blotting and serum neutralisation tests (SNT). Vaccinated mice, subse-
quently challenged with either the homologous or heterologous BTV serotype, developed viraemia by
day 3 post-infection. However, no clinical signs were observed in mice challenged with the homologous
serotype (either prime-boost or single-shot vaccinated), all of which survived for the duration of the
study. In contrast, all of the vaccinated mice challenged with a heterologous serotype, died, showing
no evidence of cross-protection or suppression of viraemia, as detected by real-time RT-qPCR or virus iso-
lation. The induction of protective, serotype-specific neutralising antibodies in IFNAR / mice, indicates
potential for the use of plant-expressed BTV VP2s as subunit vaccine components, or as a basis for
serotype-specific serological assays.
 2019 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Bluetongue virus (BTV) infects a wide range of domesticated
and wild ruminants, causing the severe clinical disease
‘bluetongue’ (BT) primarily in naïve sheep and some deer species
[1–3]. Bluetongue outbreaks in non-endemic regions of the world,
as well as those caused by exotic BTV strains/serotypes in endemic
regions, can cause major economic losses. These include fatalities
(mainly among sheep), loss of productivity and reproductiveperformance (in both cattle and sheep), restrictions of animal
movement and trade [4,5], as well as the costs of vaccination pro-
grammes and surveillance measures, which are required to
demonstrate eradication before trade restrictions can be lifted
[5,6].
Bluetongue virus is the type species of the genus Orbivirus,
within the family Reoviridae [7]. The BTV genome is composed of
ten linear segments of dsRNA, encoding seven structural proteins
(VP1–VP7) and five non-structural proteins (NS1–NS5) [8,9]. The
outer capsid of BTV is composed of two proteins, VP2 and VP5,
encoded by genome segment-2 and -5 (Seg-2 and Seg-5), respec-
tively. VP2 mediates cell attachment during initiation of infection
and elicits a protective neutralising antibody response in infected
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unit vaccines [10].
Vaccines containing live attenuated BTV strains have been used
in southern Europe and in endemic regions of South Africa and the
USA [2,11,12]. Inactivated bluetongue viruses have also been used
successfully as vaccines, particularly to combat the emerging BT
outbreaks in Europe [2,13–15]. Although both of these vaccine for-
mats can be effective as a means of BT control, they are not com-
patible with serological assays to distinguish infected from
vaccinated animals (DIVA). In addition, the Live ‘attenuated’ BTV
vaccine-strains (LAVs), cause infection in the vaccinated host and
can generate severe clinical disease, with a significant level of vir-
aemia in naïve individuals of some sheep breeds/populations
[13,16]. This can lead to infection of Culicoides midges (the main
arthropod vectors for BTV) during feeding on the vaccinated host,
resulting in onward transmission of the virus [17–19]. The use of
LAVs therefore contributes to the overall genetic diversity of the
circulating virus pool, providing opportunities for genome-
segment reassortment between vaccine and field strains. Reassort-
ment generates progeny viruses containing novel combinations of
genome segments derived from different parental strains, that
can have different transmission and virulence characteristics
[16,20–22].
Recombinant BTV proteins expressed in heterologous systems
can assemble into virus-like particles (VLPs) and represent candi-
date materials for use in subunit vaccines [23,24]. Plant based
expression systems have several advantages for production of viral
antigens, including no possibility of infection, reassortment, or
reversion to virulence and consequently minimal biocontainment
requirements, as well as freedom from contamination with the
other viral proteins, making their use compatible with DIVA assays
[13,14].
Bacterial expressed VP2 has previously been explored as a sub-
unit vaccine component, although incorrect protein folding
resulted in loss of conformational epitopes and poor solubility,
reducing both protein yield and vaccine efficacy [25].
Baculovirus-expressed VP2, VP5 and VP7 [26], or virus-vectored
delivery systems (e.g. Modified Vaccinia Ankara (MVA)) [27–29]
have also been used to vaccinate IFNAR / knockout mice,
although two doses of MVA were required to elicit protection
against challenge with a homologous BTV serotype [28,29].
Plant-based expression systems produce large amounts of soluble
and readily purifiable proteins with relatively low maintenance
costs, and are now widely used for recombinant protein expression
[30,31].
This paper describes vaccination/challenge studies showing
that VP2 of BTV-4 and BTV-8 expressed in tobacco plants (Nico-
tiana benthamiana) can be used to raise neutralising antibodies
and a protective response in IFNAR/ mice.2. Materials and methods
2.1. Expression construct and plasmid design
Nucleotide sequences for Seg-2 of BTV-4 (KP821064 - virus iso-
late [MOR2009/09]) and BTV-8 (KP821074 - virus isolate
[NET2008/03]) available from GenBank, were used to generate
constructs to express VP2 in Nicotiana benthamiana. The gene
sequences, codon optimised for plant expression, were synthesised
by GeneArt (ThermoFisher Scientific) with a 6x His-tag at the
C-terminus (to enable purification by immobilised metal affinity
chromatography (IMAC)) and flanking AgeI and XhoI restriction
sites. These DNA constructs were cloned individually into pEAQ-
HT expression vectors [24,30] to generate pEAQ-HT-BTV4-VP2
and pEAQ-HT-BTV8-VP2.2.2. Transient expression
pEAQ-HT-BTV4-VP2 and pEAQ-HT-BTV8-VP2 were transformed
into Agrobacterium tumefaciens (strain LBA4404) then cultured for
48 hrs at 28 C at 220 rpm in Luria-Bertani medium supplemented
with 50mg/mL rifampicin and kanamycin. Cultures were pelleted
by centrifugation at 2500g and re-suspended in MMA buffer
(0.1 M MES, pH 5.6, 10 mM MgCl2 and 100 mM acetosyringone) to
an OD600nm of 0.4. Bacterial suspensions were incubated at room
temperature for 30 min then pressure infiltrated into 3-week-old
tobacco plant leaves [24].2.3. Protein purification
Infiltrated plant leaves were harvested at day 8 post-infiltration,
weighed and homogenised in 3x (w/v) of extraction buffer (20 mM
NaH2PO4, 300 mM NaCl, 10 mM Imidazole, 1 mM DTT, pH 8, EDTA-
free protease inhibitor (Roche)). Homogenates were filtered
through two layers of Miracloth (Merck Millipore) then centrifuged
at 14,000g for 15 min.
Expressed VP2 proteins were purified from the supernatant by
immobilised metal affinity chromatography (IMAC) at 4 C. Plant
lysates were passed through a Ni-NTA agarose resin column
(Thermo Fisher Scientific). One column volume of wash buffer
(20 mM NaH2PO4, 300 mM NaCl, 20 mM Imidazole, 0.1% Triton
X-100, pH 8) was added, followed by an incubation period of
1 hr. rVP2 proteins were recovered in 2 mL fractions by adding elu-
tion buffer (20 mMNaH2PO4, 300 mMNaCl, 250 mM Imidazole, pH
8). Desalting of the recovered fractions was performed using PD-10
columns (GE Healthcare).
The purified proteins were mixed 1:1 in sterile glycerol and
stored in 2 mL aliquots at –20 C. Proteins were analysed by SDS-
electrophoresis on NuPAGE Bis-Tris Mini acrylamide gels (4–12%
w/v). All gels were stained with InstantBlue (Expedeon).2.4. IFNAR / mouse vaccination and challenge studies
Nine groups of six IFNAR /mice (a total of 54 mice) were vac-
cinated by intraperitoneal injection, with 5 mg per injection of rVP2
from BTV-4, or BTV-8, or phosphate-buffered saline (PBS), mixed
with 100 mL Montanide ISA V50. In the first study, two groups of
mice were immunised with 2 doses given 2 weeks apart (prime
and boost), of rVP2 of BTV-4, two groups with rVP2 of BTV-8 and
two groups with PBS (as unvaccinated controls). Two weeks after
the second vaccination, each group of mice was challenged with
either BTV-4 or BTV-8 (Table 1).
In the second study, groups of 6 mice were immunised with a
single dose of rVP2 from BTV-8, or PBS, mixed with 100 mL Mon-
tanide ISA V50, then challenged 2 weeks later with BTV-8, or
BTV-4 (Table 1). All of the mice were monitored daily throughout
the study and clinical signs recorded (data not shown).2.5. Challenge studies
Mice were challenged with a lethal dose containing 103 pfu of
BTV-4 [COR2004/01 E1/BHK2], or BTV-8 [FRA2006/01 E1/BHK1]
by intraperitoneal injection. For study 1 (prime and boost vaccina-
tion), blood samples were collected in EDTA on day 0 (pre-
vaccination), on day 28 post-vaccination (dpv)/pre-challenge, and
on days 3, 5, 7 and 25 post-challenge (dpc). For study 2 (single vac-
cine dose), blood samples were collected on 14 dpv/(pre-challenge)
and days 3, 6 and 21 post-challenge (dpc).
Table 1
IFNAR / rVP2 BTV-4 and BTV-8 vaccination and challenge regime.
Group
(n = 6)
Vaccination Challenge
Day 0
(prime)
Day 14
(boost)
Day 14 Day 28
Study 1 – BTV-4 challenge
Group 4A
rVP2-BTV-4 vaccinated
Homologous BTV-4 Challenge
BTV-4 BTV-4 – BTV-4
Group 4B
rVP2-BTV-8 vaccinated
Heterologous BTV-4 Challenge
BTV-8 BTV-8 – BTV-4
Group 4C
PBS vaccinated control
BTV-4 challenge
PBS PBS – BTV-4
Study 1 – BTV-8 challenge
Group 8A
rVP2-BTV-8 vaccinated
Homologous BTV-8 Challenge
BTV-8 BTV-8 – BTV-8
Group 8B
rVP2-BTV-4 vaccinated
Heterologous BTV-8 Challenge
BTV-4 BTV-4 – BTV-8
Group 8C
PBS vaccinated control
BTV-8 challenge
PBS PBS – BTV-8
Study 2 – Single-dose vaccination
Group 8SA
rVP2-BTV-8 vaccinated
Homologous BTV-8 Challenge
BTV-8 – BTV-8 –
Group 8SB
rVP2-BTV-8 vaccinated
Heterologous BTV-4 Challenge
BTV-8 – BTV-4 –
Group 8SC
PBS vaccinated control
BTV-8 challenge
PBS – BTV-8 –
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Total viral RNA was isolated from blood samples (100 mL per
sample) using the Direct-zol RNA MiniPrep Plus kit with TRI/
Reagent (Zymo Research). A one-step real-time RT-qPCR was then
performed using the SuperScript III Platinum qRT-PCR Kit (Invitro-
gen), targeting a conserved region on BTV Segment-10 [32]. BTV
genome copy number/mL was determined by generating a standard
curve using RNA transcribed using a T7 promoter, from a cDNA
copy of BTV Segment-10. Purified Seg-10 ssRNA was quantified
using the Qubit Fluorometer and Qubit RNA HS Assay Kit (Life
Technologies), where viral RNA copy numbers were calculated
for each reaction using the formula (Y = X/(a  680) 
6.022  1023), where Y = dsRNA molecules/mL; X = g/mL of dsRNA;
a = viral genome length in nucleotides (BTV Seg-10 = 822 bp);
680 is the average molecular weight per nucleotide of dsRNA [33].
Genome copy number/mL was calculated from CT values using a
standard and the formula: Y = aX + b, where Y = concentration
(genome copy number/mL); a = slope; b = intercept and X = CT value.
The efficiency of the assay was calculated using the formula: E%
= (10-1/slope 1) 100. CT values were plotted as the dependent and
BTV Seg-10 transcript RNA standards as the independent variable.
2.7. Serum neutralisation test (SNT)
SNTs were performed as described by Haig et al. [34] using Vero
cells. Plates were scored for cytopathic effect (CPE) on days 5–7,
with the final read used to determine neutralisation titre as the
dilution of serum giving a 50% end-point.
2.8. Western blot
Purified rVP2 BTV-4 and BTV-8 analysed by SDS-PAGE were
transferred onto a 0.45 mM nitrocellulose membrane (BioRad) at100 mA and 4 C for 90 min in standard transfer buffer (10% SDS,
20 mM Tris/HCl (pH.7.5) 150 mM glycine 20% isopropanol). Mem-
branes were incubated in blocking buffer (50 mM Tris-HCl pH 7.5,
150 mM NaCl, 5% (w/v) powdered skimmed milk) for 15 min. To
detect the purified rVP2 proteins, a primary detection antibody
directed against Penta-His BSA-free mouse monoclonal IgG1 (Qia-
gen) was used. To detect VP2-specific antibodies, serum samples
collected from the mouse challenge studies were used as primary
antibody. For both blots, a secondary detection antibody, anti-
mouse goat F (Ab) 2 fragment IgG H + L peroxidase (Beckman/Coul-
ter), diluted 1:750 in blocking buffer was applied. Blots were devel-
oped using a chemiluminescent substrate (Bio-Rad).
2.9. Indirect ELISA
An Indirect ELISA (I-ELISA) was optimised using purified rVP2 of
BTV-4 and BTV-8. The VP2 proteins were diluted in coating buffer
(0.05 M carbonate-bicarbonate buffer, pH 9.6) at 2 mg/mL and used
to coat 96-well polystyrene maxisorp ELISA plates, at 4 C over-
night. Plates were then washed 3x with 1x PBS containing 0.05%
(v/v) Tween-20. Blocking buffer (5% w/v BSA in PBS) was added
to each well, plates were covered and incubated at 37 C for 1 hr,
then washed 3x as previously described. Test serum (100 mL) was
added, diluted in blocking buffer (1:10) and incubated for 1 hr at
room temperature. Plates were then washed 3x as previously
described. Secondary anti-mouse detection antibody (100 mL
diluted 1:750) conjugated to horseradish peroxidase was added
to each well, incubated at room temperature for 1 hr, then washed
3x. SigmaFast OPD substrate (100 mL) was added to each well,
plates incubated in the dark for 15 min then absorbance measured
at 450 nm. Sample OD values were normalised by subtracting the
OD value of blank controls. A cut-off value for positive samples
was determined as the mean of the negative control plus one stan-
dard deviation.
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Significant differences in group neutralisation titres and real-
time RT-qPCR CT values were determined using the Kruskal-
Wallis test, Minitab version 17.2.11. Ethics statement
All mouse studies were performed at the National Veterinary
School, Maisons Alfort, France (UMR1161, INRA-ANSES-ENVA).
Immunisation protocols were approved by the ethics committee
at The Pirbright Institute (license number 70/6133) and ANSES-
ENVA-UPEC (license number 20/12/12-25B). Virus isolates were
provided by E. Breard and C. Sailleau (Bluetongue national refer-
ence laboratory, ANSES).3. Results
3.1. Plant expression of rVP2 of BTV-4 and BTV-8
His-tagged rVP2s of BTV-4 and BTV-8, expressed at high levels
(1.5 mg/mL each) in tobacco plants and IMAC purified, were sol-
uble suggesting that they retain a native conformation. The sizeTable 2
Mean neutralisation titres of mouse-antisera post-vaccination.
Group nAb titres by SNT (Log10)
(28 dpv)
BTV-4 BTV-8
Group 4A: rVP2 BTV-4
prime/boost vaccinated
2.96 NT
Group 4B: rVP2 BTV-8
prime/boost vaccinated
<2 NT
Group 4C: Control
(pooled sera)
<2 NT
Group 8A: rVP2 BTV-8
Prime/boost vaccinated
NT 2.16
Group 8B: rVP2 BTV-4
prime/boost vaccinated
NT <2
Group 8C: Control
(pooled sera)
NT <2
NT = Not tested due to limited volumes. The antisera frommice in groups 4A, 4B, 8A
and 8B were tested individually for neutralising antibodies against the relevant,
homologous or heterologous challenge strain, prior to challenge (Table S1). Antisera
from control groups 4C and 8C were pooled prior to testing. The limit of detection
was a neutralisation titre of 2 (Log10). No neutralising antibodies were detected in
pooled or individual mouse sera at day 0 (pre-vaccination).
Table 3
Mean ELISA OD values for mice prime/boost vaccinated with rVP2 of B
Group
(pooled sera)
Normalised OD ±
Day 0 pv.
rVP2 BTV-4
Group 4A:
rVP2 BTV-4 prime/boost vaccinated
0.07
Group 4B:
rVP2 BTV-8 prime/boost vaccinated
0.13
Group 4C:
PBS vaccinated control (pooled sera)
0.03 ± 0.01**
Group 8A:
rVP2 BTV-8 prime/boost vaccinated
0.14
Group 8B:
rVP2 BTV-4 prime/boost vaccinated
0.14
Group 8C:
PBS vaccinated control (pooled sera)
0.06 ± 0.05
Data for individual animals in groups 4A, 4B, 8A and 8B are given in T
the mice in group 4B. **±1 SD.and identity of the purified proteins was confirmed by SDS-PAGE
and western blot analysis (Fig. S1), generating a major band
migrating at the expected size of 110 kDa for monomeric VP2.
In both cases this protein reacted with antibody against Penta-
His by western blot.
Supplementary data associated with this article can be found, in
the online version, at https://doi.org/10.1016/j.jvacx.2019.100026.3.2. The antibody response to prime/boost rVP2 vaccination
Six groups of six IFNAR / mice were vaccinated (prime and
boost), two groups each with purified rVP2 of BTV-4, or rVP2 of
BTV-8, or 1x PBS (the control groups). These groups were subse-
quently challenged with BTV-4 or BTV-8 (Table 1). Mice in group
4A (vaccinated with rVP2 of BTV-4), developed a detectable level
of neutralising antibodies (nAbs) against the homologous BTV-4
by 28 dpv (pre challenge) (Tables 2 and S1). However, nAbs against
BTV-4 were below the sensitivity of the assay (<2), in mice from
group 4B, which were vaccinated with the heterologous rVP2 of
BTV-8.
Comparable results were also obtained for mice in group 8A,
which developed a slightly weaker nAb response against BTV-8
after vaccination with rVP2 of BTV-8 (Tables 2 and S1). Group 8B
mice, which were vaccinated with rVP2 of BTV-4, did not generate
detectable nAb levels (<2) against BTV-8 (Tables 2 and S1). No nAbs
were detected against either BTV serotype in pooled sera from the
control groups (groups 4C and 8C) (Tables 2 and S1). These results
are consistent with a serotype-specific nAb response to the rVP2
proteins.
Antisera from mice in each of the vaccination groups were also
tested post-vaccination (pre-challenge) by ELISA against the
homologous rVP2 proteins of BTV-4 or BTV-8 (Table 3). Although
the results for individual animals were more variable by ELISA
(Table S2) than by SNT (Table S1), there was little detectable
response in any of the groups to rVP2 of either serotype on day 0
(pre-vaccination). However, by day 28 dpv, the mean OD values
(as well as those for almost every individual animal) against
rVP2 of the homologous serotype had risen, with little or no
increase in the response to the rVP2 protein of the heterologous
serotype, or in the control animals against either serotype (Tables
3 and S2).
Protein bands of the expected size for BTV rVP2 (110 kDa),
were also detected in the purified protein preparations by western
blot using the antisera taken at day 28 dpv from mice prime/boost
vaccinated with rVP2 of the homologous serotype. No equivalentTV-4 or BTV-8.
1 SD
Day 28 pv.
rVP2 BTV-8 rVP2 BTV-4 rVP2 BTV-8
0.01 0.40 0.11
0.05 0.07* 0.69*
0.02 ± 0.01 0.03 ± 0.06 0.16 ± 0.32
0.09 0.08 0.63
0.01 0.52 0.07
0.02 ± 0.02 0.00 ± 0.04 0.01 ± 0.14
able S2. * Sufficient serum for SNT was only obtained for three of
Fig. 2. Survival and mean genome copy numbers/mL for prime/boost vaccinated mic
vaccination 14 days apart with rVP2 of either BTV-4 (group 4A) or BTV-8 (group 4B) prior
4C was also challenged with BTV-4. Panel A: Survival Curves. Animals in the homologou
mice in the heterologous challenge group 4B had died by day 3 pc, and the three remainin
mice had died by day 3 pc, two more had died by day 5 pc and the remaining mouse had d
days 3, 5, 7 and 25 pc. At day 3 pc, viraemia was significanty lower in animals in group
Fig. 1. Western blots using pooled antisera from vaccinated IFNAR / mice at
day 28 dpv. Pooled antisera from groups 4A and 8B were tested against rVP2 of
BTV-4, while pooled antisera from groups 8A and 4B were tested against rVP2 of
BTV-8. In each case bands were detected at 110 kDa (the MW of the VP2
monomer) as indicated by arrowheads. No equivalent bands were detected by the
negative (-ve) control sera taken from groups 4C and 8C, when tested against rVP2
of BTV-4 or BTV-8 respectively.
P.C. Fay et al. / Vaccine: X 2 (2019) 100026 5protein bands were detected using any of the negative control sera
(Fig. 1). Due to limitations on the amount of available sera, western
blots were not performed against the heterologous rVP2 proteins.3.3. Challenge studies of prime/boost vaccinated mice
All mice vaccinated with rVP2 BTV-4 survived the homologous
serotype challenge with BTV-4 (Fig. 2A), although they did become
infected developing levels of viraemia that peaked on days 5 to 7
pc, which then declined by day 25 pc In contrast, three of the mice
in both groups 4B (vaccinated with rVP2 of BTV-8) and group 4C
(mock vaccinated with PBS) had died by day 3 pc. The three
remaining animals in both the heterologous rVP2 and mock vacci-
nated control groups (groups 4B and 4C), had all died by day 5 pc,
except for one animal in the mock vaccinated control group that
died by day 7 pc. The mean BTV-4 viraemia on day 3 pc, in group
4A mice vaccinated with the homologous rVP2, was significantly
lower (1.89  103 genome copies/mL (P = 0.028) than in the 3 sur-
viving mice in the mock vaccinated control group 4C (at
2.38  105 genome copies/mL), which was also lower than in the
three surviving mice in group 4B previously vaccinated with
rVP2 of the heterologous serotype BTV-8 (4.28  106 genome
copies/mL) (Fig. 2B, Table S3).
Group 8A mice had generated a low level of antibodies to rVP2
of BTV-8 by day 0 pc, as detected by both SNT (Table 2) and ELISA
(Table 3). These antibodies did not detect rVP2 of BTV-4 in either
assay. The group 8A mice challenged with BTV-8 all survived to
the end of the experiment on day 25 pc (Fig. 3A). Group 8A mice
developed peak viraemia on days 3 to 7 pc (2.38  104 toe challenged with BTV-4. Two groups of 6 IFNAR / mice received a prime/boost
to challenge with BTV-4, 14 days later. The mock vaccinated negative control group
s challenge group 4A survived for the duration of the challenge study. Three of the
g mice had all died by day 5 pc. In the unvaccinated challenge group 4C, three of the
ied by day 7 pc. Panel B: Mean genome copy/mlL of blood from the surviving mice at
4A compared to those in the control group, 4C (*P = 0.028).
Fig. 3. Survival and mean genome copy numbers/mL for prime/boost vaccinated mice challenged with BTV-8. Two groups of 6 IFNAR / mice received a prime/boost
vaccination 14 days apart, with rVP2 of either BTV-8 (group 8A) or BTV-4 (group 8B) prior to challenge with BTV-8, 14 days later. The mock vaccinated negative control group
8C was also challenged with BTV-8. Panel A: Survival Curves. Animals in group 8A survived for the duration of the challenge study. Mice in group 8B had all died by day 5 pc.
In group 8C, three of the mice had died by day 3 pc, the remaining three mice had all died by day 5 pc. Panel B: Mean BTV genome copy/mL of blood from the surviving mice at
days 3, 5, 7 and 25 pc.
6 P.C. Fay et al. / Vaccine: X 2 (2019) 1000262.56  106 genome copies/mL by day 3pc) (Fig. 3B, Table S4), higher
than the BTV-4 viraemia in the equivalent BTV-4 vaccinated/chal-
lenge group 4A (which varied from undetectable to 2.17  104
BTV-4 genome copies/mL on day 3 pc) (Fig. 2B, Table S4).
The mean level of BTV-8 viraemia in the homologous challenge
group 8A, was not significantly different from that detected in the
three surviving mice in the mock vaccinated control group 8C at
day 3 pc (P = 0.121), suggesting that in this study the level of early
viraemia is not a good predictor for the severity of clinical out-
comes after challenge (Fig. 3B). Mice vaccinated with rVP2 of
BTV-4 (group 8B) and mock vaccinated control mice (group 8C)
challenged with BTV-8 had all died by day 5 pc confirming the
serotype-specific nature of the protective response (Table S5).
However, as already observed with the BTV-4 rVP2 vaccinated
mice (Table S4), the level of viraemia in the three surviving mock
vaccinated mice in group 8C, on day 3 pc (1.71  105 to
6.56  105 genome copies/mL – mean of 2.73  105) (Table S3),
was lower than in the heterologous rVP2 BTV-4 vaccinated mice
after challenge with BTV-8 (group 8B) at 2.65  105 to 6.22  106
genome copies/mL – mean of 1.91  106 (Table S4). This suggests
that the immune response to rVP2 may have increased early repli-
cation and the level of viraemia caused by the heterologous BTV
serotype, for both BTV-4 and BTV-8.
Virus isolation attempted from EDTA blood samples collected at
day 25 pc for groups 4A and 8A were unsuccessful using BSR and
KC cell lines (data not shown).3.4. Challenge study using a single dose rVP2 BTV-8 vaccination
A single dose vaccination study was also carried out in IFNAR
/ mice, using rVP2 of BTV-8, to see if a single shot vaccination
would confer protection. Fourteen days post-vaccination the mice
were challenged with either BTV-8 or BTV-4 (groups 8SA and 8SB
respectively). The PBS vaccinated control group 8SC was also chal-
lenged with BTV-8. All of the vaccinated mice in group 8SA, sur-
vived for the duration of the study (21 dpc). No cross-protection
was detected in mice receiving the BTV-4 heterologous challenge,
which had all died by day 8 pc (Fig. 4A).
All of the challenged mice developed viraemia, with a higher
level of genome copies/mL detected in group 8SB and 8SC
(6.64  105 to 2.22  105 genome copies/mL, respectively) com-
pared to group 8SA (1.37  103 genome copies/mL) by day 3 pc
(P = 0.05). Peak viraemia was reached by day 6 pc for both the
heterologous vaccinated and PBS vaccinated control animals
(groups 8SB and 8SC – mean of 6.0  106 to 4.79  106 genome
copies/mL, respectively). However, mice in the homologous group
8SA developed significantly less viraemia compared to mice in
groups 8SB and 8SC (P = 0.003). Viraemia in the homologous chal-
lenge mice dropped after day 3 pc and no RNA was detected in any
of these animals by the end of the study (Fig. 4B, Table S5). Unfor-
tunately, insufficient blood was recovered from individual animals
in this experiment to evaluate the production of either neutralising
or non-neutralising VP2-specific antibodies.
Fig. 4. Survival and mean genome copy numbers/mL in mice after single dose vaccination with rVP2 of BTV-8. Two groups of 6 IFNAR / mice received a single
vaccination with rVP2 of BTV-8 prior to challenge 14 days later. Group 8SAmice were challenged with the homologous BTV-8, while group 8SBmice were challenged with the
heterologous BTV-4. The PBS vaccinated control group 8SC was also challenged with BTV-8. Panel A: Survival Curves. Mice in the homologous challenge group 8SA survived
for the duration of the challenge study. Mice in the PBS vaccinated control group 8SC had all died by day 8 pc, while those in the heterologous (BTV-4) challenge group 8SB
had all died by day 9 pc. Panel B: Mean BTV genome copy/mL of blood from surviving mice at days 3, 6 and 21 pc. At days 3 and 6 pc, viraemia was significantly lower in
animals in group 8SA compared to animals in group 8SB and 8SC (*P = <0.05).
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Recombinant VP2s of BTV-4 and BTV-8 were successfully and
abundantly expressed as soluble proteins with His-tags in tobacco
plants (N.benthamiana), then purified by affinity chromatography.
These rVP2 proteins raised a serotype-specific and protective
immune response in vaccinated IFNAR / mice, in the absence
of the other BTV proteins. The vaccinated mice all survived a viru-
lent homologous challenge, and although they still became
infected they displayed no clinical signs and maintained body
weight. The levels of nAbs that were detected against the homolo-
gous BTV serotype, after prime/boost vaccinations with rVP2, are
considered likely to have played an important role in the protec-
tion observed, although this study does not directly differentiate
the roles and importance of neutralising and non-neutralising anti-
bodies, or any potential T-cell mediated response in protection.
Although BTV RNA was detected by real-time RT-qPCR in the
surviving homologous challenge groups on day 25 post-
challenge, attempts to re-isolate the virus were unsuccessful. This
may reflect the haemagglutination activity known to be associated
with BTV particles, binding them to circulating erythrocytes even
in the presence of nAbs, rather than a significant level of persistent
infectivity [3,35,36].
Previous studies in IFNAR /mice vaccinated with VP2 purified
from intact BTV virions or expressed by recombinant baculovirus,
have shown partial protection against virulent challenge with
homologous serotypes [37,38]. Prime/boost vaccination strategies
using rDNA/rMVA protocols, expressing a cocktail of VP2 andVP5 from BTV-4, were also partially protective [25,39]. A similar
study design found that IFNAR / mice vaccinated using a
rMVA/rDNA or rMVA/rMVA prime/boost strategy for VP2 of BTV-
8 alone, were fully protected post-challenge with the homologous
virus serotype [29].
Cross-serotype neutralising antibody and protective immune
responses have been reported after sequential vaccination/infec-
tion with MLV from two different BTV serotypes, which were sig-
nificantly enhanced following challenge with a third heterotypic
serotype (44). The production of cross-reactive nAbs, even at low
titres, could prime an enhanced secondary immune response to
infection by a heterologous strain, potentially resulting in faster
nAb proliferation and a more protective cross-reactive response.
The development of cross-reactive nAbs is thought to reflect the
presence of a proportion of the neutralising epitopes on VP2, that
are conserved or shared between different BTV serotypes [40]. Ear-
lier studies have reported low-level or one-way serological cross-
reactions between different BTV serotypes in cross neutralisation
and cross-protection studies, that reflect the phylogenetic relation-
ships observed between their VP2 proteins [41,42]. However in the
study described here, mice vaccinated with rVP2 alone were
unprotected against a virulent heterologous-serotype challenge,
indicating the absence of a cross-protective immune response
between BTV-4 and BTV-8 (which are distantly related VP2 pro-
teins [42]).
After heterologous challenge with either BTV-4 or BTV-8, the
surviving single shot and prime/boost rVP2 immunisedmice devel-
oped a higher mean viraemia on day 3, than in the unvaccinated
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immunisation with rVP2 could have increased the early replication
and viraemia caused by the heterologous challenge virus.
A higher BTV-genome copy number was detected in blood sam-
ples taken on day 3 post challenge, from mice that received a
prime/boost vaccination with rVP2 of BTV-8, followed by a homol-
ogous serotype challenge when compared to mice that had
received only a single shot with the same protein. Although this
may in part reflect experimental variation, the presence of higher
levels of non-neutralising antibodies to rVP2 of BTV-8 in the
prime/boost vaccinated group, may have enhanced the early infec-
tion of cellular components of the immune system [43], leading to
a more rapid early rise in viraemia, even though both groups of
mice were protected and survived for the duration of the
experiment.
Any potential for vaccine-associated enhancement of infection,
could have a major impact on the control and epidemiology of BTV,
particularly in areas where more than one serotype is circulating,
or multivalent (multi-serotype) vaccines are being used.
The antibodies to rVP2 detected by western blot and ELISA
(both of which may be non-neutralising), in sera taken from each
of the rVP2 prime/boost vaccination groups on day 28 pv (day 0
pre-challenge), and nAbs detected by SNT, are thought likely to
play a significant collective role in the serotype-specific protection
that was observed. Although the role of non-neutralising antibod-
ies in protection is unclear, it is possible that during the early
stages of infection the level of viraemia could be reduced through
opsonisation of infected cells. This could result in a reduction in the
development of severe clinical signs and/or a reduction of viraemia
below levels transmissible to midges, thus also reducing the risk of
onward infection [44].
Cell-mediated immune responses (e.g. against the NS1 ‘tubule’
protein) have been shown to be protective against heterologous
BTV serotypes [45]. A strong cell-mediated immune response initi-
ated during early infection that influences the protective humoral
response, has been observed in studies with different BTV sero-
types, resulting in reduced viraemia prior to the development of
neutralising antibodies [45–48]. It is possible that cell-mediated
immune responses (against VP2) could play some role in the pro-
tection observed after homologous serotype challenge in the cur-
rent study.
A strong nAb response is highly dependent on accurate epitope
display. It is therefore important when using recombinant
expressed VP2 to retain a relevant/native protein structural confor-
mation [37,49–51]. The soluble nature of the rVP2 proteins of BTV-
4 and BTV-8 that were successfully expressed in tobacco plants,
suggests that they retain a native conformation. This expression
system eliminates the possibility of contamination with other viral,
mammalian or insect host proteins, or contamination with infec-
tious BTV that could affect the range of viral-antigens and conse-
quently the range of antibodies and cross-reactions detected. The
plant based methods used do not require containment or large
scale sterile facilities for protein production, are readily scalable
and very rapid, taking approximately two weeks from construct
design to the production of the purified protein, further reducing
overall costs [30].
The results described here indicate potential for use of recombi-
nant expressed VP2s as sub-unit vaccine components. The immune
response to plant-expressed rVP2 from a wider range of different
BTV serotypes (including BTV-4 and BTV-8) is currently being
investigated in both mice and sheep. This includes an analysis of
the roles of neutralising and non-neutralising antibodies in protec-
tion, after both single-shot and prime-boost immunisation and the
extent of immune cross-reactivity after sequential or simultaneous
vaccination with different rVP2s, before and after challenge with
different serotypes. The results obtained will be compared to theknown phylogenetic relationships of the VP2 proteins of these
viruses [51] and may help in development of efficacious multi-
serotype, DIVA compatible vaccines and vaccination strategies,
that pose no risk of reassortment, reversion to virulence or onward
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